The second round of drug reform after the new medical reform has begun to take shape

The five major adjustments were made at the relevant forum of the Guangzhou National Pharmaceutical Trade Fair just now. Fu Wenjun, Deputy Director of the Pharmaceutical Price Division of the Price Bureau of Zhejiang Province disclosed the key contents of the country’s future drug price management in related speeches, which mainly include several major aspects:

The first is to complete the second round of medical drug price adjustment pricing work. By the end of 2012, all chemical pricing adjustments will be completed. In 2013, the price adjustment of Chinese patent medicines will be completed.

The second is to improve the scope of government pricing. For example, Guangdong provinces and provinces have piloted prescription drugs that are not in the category of medical insurance catalogs, have large clinical doses, and have a large impact on patients, and are also included in government pricing. Fu Wenjun said that the pilot project in Guangdong is a way of thinking on behalf of the country. The scope of future government pricing may not follow medical insurance. For example, the price of OTC drugs that are fully competitive in some markets may not necessarily be priced by the government or the highest retail price. management.

The third is to strengthen the supervision of circulation, including the ex-factory price declaration and the control of the circulation rate. Fu Wenjun pointed out that in actuality, the draft of the draft of the regulatory documents on the circulation of foreign exchange rates previously issued by the country has been temporarily suspended. However, the clear difference in the circulation rate is not much different from the circulation difference rate in the previous round of pricing, and even there is an increase. This shows that there is no problem in the area of ​​drug circulation from the account margin, but in fact there are big differences, reflecting the non-standard ex-factory price of drugs, mainly caused by differences in the company's cost management and operating level.

Fu Wenjun believes that if the business environment of the hospital does not change, the drastic reform of drugs alone may bring more serious drawbacks. However, if the compensation mechanism of public hospitals is improved and the business environment changes, the spread rate of drugs will be controlled. Certainly still will be implemented.

Fourth, the principle of review of drug costs has changed. Fu Wenjun pointed out that because there is often a lot of approvals for a product in China, the maximum retail price policy is the most suitable management method in China. However, after the implementation of the maximum retail price, the ex-factory price and retail price often occur due to various factors of market competition. There is a huge gap between them, which inspires instability.

Fifth, the pricing of basic drugs may change. The new drug directory will soon be introduced. First, it may continue the current retail price guideline. Second, the implementation of a unified price, the hospital purchases at a uniform price, sales at a uniform price, or an increase in the basis of a unified price, the medical insurance department in accordance with the unified price For reimbursement, Medicare fixed-point retail pharmacies also sell at the prescribed rate.